Eli Lilly & Co (LLY): Gross Profit
$54.13B
Year ended 2025-12-31
+35.2%
3-year compound annual growth
+23.2%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.13B | +47.8% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $36.62B | +35.4% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $27.04B | +23.4% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $21.91B | +4.3% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $21.01B | +10.2% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $19.06B | +8.3% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $17.60B | +4.7% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $16.81B | +8.3% | 2021-02-17, From 2018-01-01 |
| 2017-12-31 | $15.53B | n/c | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | $15.51B | n/a | 2019-02-19, From 2016-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Eli Lilly & Co (LLY) | 2025-12-31 | $54.13B | +47.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $48.63B | -0.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $46.51B | +1.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $42.96B | +8.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $63.94B | +4.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $25.01B | +7.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.94B | +10.8% |
| Viatris Inc (VTRS) | 2025-12-31 | $5.01B | -10.8% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $10.35B | +9.1% |
Compare LLY, MRK, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗